Abstract
The indigenous people of Brazil present several cases and deaths, affecting 158 peoples, with high vulnerability and limited access to health services. The objective is to investigate the clinical characteristics of severe acute respiratory syndrome by COVID-19 in indigenous peoples of Brazil. The epidemiological study, descriptive, from the data of the platform opendataSUS referring to the SIVEP-GRIPE in the period 01/01/2020 until 31/08/2020. Profile variables, signs and symptoms, and risk/comorbidities factors. The data were analyzed by Bioestat 5.3. 1,207 cases and 470 deaths. Profile: male gender (59.48%) mean age 53. Signs and symptoms: fever (74.23%), cough (77.71%), sore throat (35.62%), dyspnea (69.34%), respiratory discomfort (62.80%), O2 saturation <95% (56.42%); and associated with mortality: dyspnea (80.0%) and O2 saturation <95% (69.36%). Risk factors and comorbidities (45.89%) were associated with deaths (54.04%). Comorbidities: Chronic Cardiovascular Disease (18.97%) and Diabetes Mellitus (18.97%), and associated with deaths: Chronic Cardiovascular Disease (24.46%). There was significance in the survivors vaccinated for influenza (26.18%). The public and health policies of Brazil should be directed to control the dissemination of COVID-19 in this population, that COVID-19 evolves in the same intensity, however, the indigenous have vulnerabilities that can enhance the impact of the pandemic in this population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
was not financed
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
all authors have authorized the publication
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
data are available on the opendatasus platform of the Brazilian Ministry of health
